Comments
Drug firm Lupin has received tentative approval from the US health regulator to market a generic version of Prezista tablets, used in treating HIV infection.
The company has received tentative approval from the United States Food and Drugs Administration (FDA) to market its Darunavir Ethanolate tablets in multiple strengths in the American market, Lupin said in a statement.
Darunavir tablets are indicated for the treatment of HIV-1 infections. According to IMS MAT September, 2014 sales data, Janssen’s Prezista tablets had annual US sales of $1.2 billion.
Last week, the Mumbai-based company had received US health regulator’s approval to market a generic version of ViiV Healthcare’s Epivir Tablets, used in treating HIV infection, in the American market.
Lupin shares closed at Rs 1,428.70 apiece on the BSE, down 0.21 per cent from its previous close.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.